Management of Ulcerative Colitis

Introduction to Treatment

• The American Gastroenterological Association recommends that treatment for ulcerative colitis (UC) should be tailored based on disease extent, severity, and location, with 5-aminosalicylates (5-ASA) as first-line therapy for mild-to-moderate disease and escalation to corticosteroids, immunomodulators, or biologics for moderate-to-severe disease or those who fail initial therapy 1, 2

Management of Mild-to-Moderate UC

• For patients with extensive disease, standard dose mesalamine (2-3 grams/day) or diazo-bonded 5-ASA is recommended as first-line therapy, rather than low-dose mesalamine, sulfasalazine, or no treatment 1
• Adding rectal mesalamine to oral 5-ASA therapy is recommended for better outcomes in patients with mild-to-moderate UC 2
• For suboptimal response to standard-dose mesalamine or moderate disease activity, high-dose mesalamine (>3 grams/day) with rectal mesalamine is suggested 3
• Once-daily dosing of oral mesalamine is preferred over multiple daily dosing for better adherence in patients with mild-to-moderate UC 4

Management of Moderate-to-Severe UC

• Oral corticosteroid therapy (prednisolone 40 mg daily) is appropriate for induction of remission in patients with moderate-to-severe UC 5
• After successful induction with corticosteroids, transition to maintenance therapy with 5-ASA, thiopurines, anti-TNF agents (with or without thiopurine/methotrexate), or vedolizumab is recommended 6
• For corticosteroid-resistant/dependent UC, anti-TNF therapy or vedolizumab is recommended 6

Management of Severe UC

• Severe UC should be managed jointly by a gastroenterologist and colorectal surgeon, with daily physical examination to evaluate abdominal tenderness and rebound tenderness 5, 7
• Patients with severe UC should receive intravenous fluid and electrolyte replacement, and maintain hemoglobin >10 g/dl, with administration of subcutaneous heparin to reduce thromboembolism risk 7
• For patients with acute severe UC refractory to IV corticosteroids, infliximab or cyclosporine may be considered 8

Maintenance Therapy

• Lifelong maintenance therapy is generally recommended, especially for patients with left-sided or extensive disease, to reduce relapse risk and potentially the risk of colorectal cancer 5
• Patients in remission with biologics and/or immunomodulators after prior failure of 5-ASA may discontinue 5-aminosalicylates 8

Treatment Considerations

• Patients already on sulfasalazine in remission or with prominent arthritic symptoms may reasonably choose sulfasalazine 2-4g/day if alternatives are cost-prohibitive, despite higher intolerance rates 1
• Probiotics, curcumin, and fecal microbiota transplantation are not currently recommended for routine use in UC due to insufficient evidence 3, 4

Management of Ulcerative Colitis Based on Disease Location and Severity

Treatment Recommendations

• For patients with mild or moderately active proctitis, a mesalamine 1-g suppository once daily is the preferred initial treatment, as it delivers the drug more effectively to the rectum and is better tolerated, according to the European Crohn’s and Colitis Organisation 9
• Topical mesalamine is more effective than topical steroids for treating proctitis, and combining topical mesalamine with oral mesalamine or topical steroids is more effective than monotherapy, as recommended by the European Crohn’s and Colitis Organisation 9
• For patients with mild to moderately active left-sided UC, treatment with an aminosalicylate enema ≥1 g/day combined with oral mesalamine ≥2.4 g/day is recommended, as it is more effective than oral or topical aminosalicylates, or topical steroids alone, according to the European Crohn’s and Colitis Organisation 10
• The American Gastroenterological Association recommends that patients with moderate to severe left-sided UC who do not respond to 5-ASA be treated with oral corticosteroids (prednisolone 40 mg daily) 11
• For patients with severe UC, management should be joint between a gastroenterologist and colorectal surgeon, with treatment including intravenous fluid and electrolyte replacement, maintenance of hemoglobin >10 g/dl, and subcutaneous heparin to reduce thromboembolism risk, as recommended by the British Society of Gastroenterology 12
• The European Crohn’s and Colitis Organisation recommends that patients with severe UC receive intravenous steroids (hydrocortisone 400 mg/day or methylprednisolone 60 mg/day), and that infliximab or cyclosporine may be used for patients refractory to IV corticosteroids [12] [13]

Maintenance Therapy and Special Considerations

• The American Gastroenterological Association recommends lifelong maintenance therapy for all patients, especially those with left-sided or extensive disease, and those with distal disease who relapse more than once a year, with treatment adjustment based on response to therapy 12
• Patients in remission with biologics and/or immunomodulators after prior failure of 5-ASA may discontinue 5-aminosalicylates, as recommended by the American Gastroenterological Association 13
• The European Crohn’s and Colitis Organisation suggests monitoring patients for response to therapy, with adjustment of treatment if symptoms deteriorate, rectal bleeding persists beyond 10-14 days, or sustained relief from all symptoms has not been achieved after 40 days of appropriate 5-ASA therapy, with a threshold for introducing oral steroids depending on the response to and tolerance of 5-ASA, patient's preference, and physician's practice 11

Initial Medical Management of Mild-to-Moderate Ulcerative Colitis

High-Risk Features and Treatment Strategy

• Patients with high-risk features, such as age <40 years at diagnosis, extensive disease, severe endoscopic activity, extra-intestinal manifestations, and elevated inflammatory markers, may benefit from more aggressive initial therapy or rapid treatment intensification, as they predict an aggressive disease course, according to the American Gastroenterological Association 14
• These high-risk patients may require closer monitoring and more intensive treatment to achieve optimal outcomes, with the goal of inducing and maintaining remission, as recommended by the American Gastroenterological Association 14